153 related articles for article (PubMed ID: 18097012)
1. Distinct role for CD8 T cells toward cutaneous tumors and visceral metastases.
Lengagne R; Graff-Dubois S; Garcette M; Renia L; Kato M; Guillet JG; Engelhard VH; Avril MF; Abastado JP; Prévost-Blondel A
J Immunol; 2008 Jan; 180(1):130-7. PubMed ID: 18097012
[TBL] [Abstract][Full Text] [Related]
2. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
[TBL] [Abstract][Full Text] [Related]
3. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.
Herr W; Schneider J; Lohse AW; Meyer zum Büschenfelde KH; Wölfel T
J Immunol Methods; 1996 May; 191(2):131-42. PubMed ID: 8666832
[TBL] [Abstract][Full Text] [Related]
4. Effect of artesunate on immune cells in ret-transgenic mouse melanoma model.
Ramacher M; Umansky V; Efferth T
Anticancer Drugs; 2009 Nov; 20(10):910-7. PubMed ID: 19745721
[TBL] [Abstract][Full Text] [Related]
5. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.
Lengagne R; Le Gal FA; Garcette M; Fiette L; Ave P; Kato M; Briand JP; Massot C; Nakashima I; Rénia L; Guillet JG; Prévost-Blondel A
Cancer Res; 2004 Feb; 64(4):1496-501. PubMed ID: 14973052
[TBL] [Abstract][Full Text] [Related]
7. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
Yamshchikov GV; Mullins DW; Chang CC; Ogino T; Thompson L; Presley J; Galavotti H; Aquila W; Deacon D; Ross W; Patterson JW; Engelhard VH; Ferrone S; Slingluff CL
J Immunol; 2005 Jun; 174(11):6863-71. PubMed ID: 15905528
[TBL] [Abstract][Full Text] [Related]
8. Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs.
Kimpfler S; Sevko A; Ring S; Falk C; Osen W; Frank K; Kato M; Mahnke K; Schadendorf D; Umansky V
J Immunol; 2009 Nov; 183(10):6330-7. PubMed ID: 19841169
[TBL] [Abstract][Full Text] [Related]
9. CD8+ T cells are necessary for recognition of allelic, but not locus-mismatched or xeno-, HLA class I transplantation antigens.
Borenstein SH; Graham J; Zhang XL; Chamberlain JW
J Immunol; 2000 Sep; 165(5):2341-53. PubMed ID: 10946256
[TBL] [Abstract][Full Text] [Related]
10. T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
Tjin EP; Konijnenberg D; Krebbers G; Mallo H; Drijfhout JW; Franken KL; van der Horst CM; Bos JD; Nieweg OE; Kroon BB; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Clin Cancer Res; 2011 Sep; 17(17):5736-47. PubMed ID: 21750202
[TBL] [Abstract][Full Text] [Related]
11. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-specific memory T cells are functionally active in Ret transgenic mice without macroscopic tumors.
Umansky V; Abschuetz O; Osen W; Ramacher M; Zhao F; Kato M; Schadendorf D
Cancer Res; 2008 Nov; 68(22):9451-8. PubMed ID: 19010920
[TBL] [Abstract][Full Text] [Related]
13. Targeting surface nucleolin with a multivalent pseudopeptide delays development of spontaneous melanoma in RET transgenic mice.
El Khoury D; Destouches D; Lengagne R; Krust B; Hamma-Kourbali Y; Garcette M; Niro S; Kato M; Briand JP; Courty J; Hovanessian AG; Prévost-Blondel A
BMC Cancer; 2010 Jun; 10():325. PubMed ID: 20573279
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.
Pommier A; Audemard A; Durand A; Lengagne R; Delpoux A; Martin B; Douguet L; Le Campion A; Kato M; Avril MF; Auffray C; Lucas B; Prévost-Blondel A
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):13085-90. PubMed ID: 23878221
[TBL] [Abstract][Full Text] [Related]
15. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
16. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
Mortarini R; Piris A; Maurichi A; Molla A; Bersani I; Bono A; Bartoli C; Santinami M; Lombardo C; Ravagnani F; Cascinelli N; Parmiani G; Anichini A
Cancer Res; 2003 May; 63(10):2535-45. PubMed ID: 12750277
[TBL] [Abstract][Full Text] [Related]
17. High frequencies of circulating melanoma-reactive CD8+ T cells in patients with advanced melanoma.
Letsch A; Keilholz U; Schadendorf D; Nagorsen D; Schmittel A; Thiel E; Scheibenbogen C
Int J Cancer; 2000 Sep; 87(5):659-64. PubMed ID: 10925359
[TBL] [Abstract][Full Text] [Related]
18. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.
Maeurer MJ; Necker A; Salter RD; Castelli C; Höhn H; Karbach J; Freitag K; Neukirch C; Knuth A; Jäger E
Int J Cancer; 2002 Jan; 97(1):64-71. PubMed ID: 11774245
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
